|
Market Closed -
Euronext Amsterdam
11:55:00 2026-10-21 EDT
|
Pre-market 01:42:42 | |||
| 0.8506 EUR | -0.30% |
|
0.9300 | +9.33% |
| 09-13 | Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja | MT |
| 09-11 | Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S | CI |
| Market Cap | 676M 602M 557M 504M 950M 63.76B 962M 6.68B 2.62B 33.51B 2.53B 2.48B 107B | P/E 2026 * |
30.6x | P/E 2027 * | 22.7x |
|---|---|---|---|---|---|
| Enterprise Value | 629M 560M 519M 470M 885M 59.35B 895M 6.22B 2.44B 31.2B 2.36B 2.31B 99.41B | EV / Sales 2026 * |
1.64x | EV / Sales 2027 * | 1.47x |
| Free-Float |
99.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| PHARM | Real-time | |
CBOE
| PHARM | Real-time | |
|
Tradegate
| PHGN | Real-time | |
|
London S.E.
| 0QCO | Delayed | |
|
Boerse Muenchen
| PHGN | Real-time | |
|
Berne S.E.
| PHGN | End-of-day quote | |
|
OTC Markets
| PHGUF | Delayed | |
|
Deutsche Boerse AG
| PHGN | Delayed | |
|
CBOE
| 0QCO | Real-time | |
|
Börse Stuttgart
| PHGN | Delayed | |
|
Xetra
| PHGN | Delayed |
Last Transcript: Pharming Group N.V.
| 1 day | -0.30% | ||
| 1 week | -1.12% | ||
| Current month | -4.13% | ||
| 1 month | -8.34% | ||
| 3 months | -26.32% | ||
| 6 months | -41.60% | ||
| Current year | -40.35% |
| 1 week | 0.82 |  | 0.87 |
| 1 month | 0.82 | | 0.97 |
| Current year | 0.82 | | 1.82 |
| 1 year | 0.82 | | 1.82 |
| 3 years | 0.65 | | 1.82 |
| 5 years | 0.65 | | 1.82 |
| 10 years | 0.21 | | 1.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kenneth Lynard
CEO | Chief Executive Officer | 58 | 2026-09-28 |
Leverne Marsh
CEO | Chief Executive Officer | - | 2026-09-28 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 2020-12-10 |
Mark Pykett
BRD | Director/Board Member | 62 | 2020-12-10 |
| Director/Board Member | 60 | 2021-05-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/12/25 | Free | Director | 3,613 | 0.0005% | ||
| 10/23/25 | Exercice | Executive/Senior Manager | 23,720 | 0.0035% | ||
| 10/23/25 | Sell | Chief Technology Officer | 337,500 | 0.0496% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.30% | -1.12% | -26.99% | -16.11% | 676M | |
| -1.01% | +5.13% | +58.93% | +117.36% | 1,133B | |
| -0.61% | +1.52% | +34.34% | +68.48% | 621B | |
| -1.48% | +0.47% | +23.08% | +94.76% | 503B | |
| +0.54% | +5.69% | +39.60% | +64.02% | 379B | |
| +1.07% | +1.70% | +71.06% | +45.98% | 370B | |
| +0.30% | +3.44% | +21.35% | +49.62% | 292B | |
| -0.03% | +2.55% | +1.12% | +20.94% | 262B | |
| -0.14% | +2.87% | +45.56% | +57.22% | 237B | |
| -1.88% | +0.02% | +23.77% | +97.39% | 190B | |
| Average | -0.06% | +2.78% | +29.18% | +59.97% | 398.87B | |
| Weighted average by Cap. | +0.33% | +3.73% | +40.82% | +79.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 383M 342M 316M 286M 539M 36.18B 546M 3.79B 1.49B 19.02B 1.44B 1.41B 60.59B | 417M 372M 344M 312M 587M 39.38B 594M 4.13B 1.62B 20.7B 1.57B 1.53B 65.95B |
| Net income | 17.41M 15.52M 14.37M 13M 24.5M 1.64B 24.79M 172M 67.59M 864M 65.33M 63.97M 2.75B | 23.39M 20.85M 19.3M 17.47M 32.91M 2.21B 33.3M 231M 90.8M 1.16B 87.76M 85.93M 3.7B |
| Net Debt | -46.69M -41.61M -38.52M -34.86M -65.68M -4.41B -66.46M -462M -181M -2.32B -175M -172M -7.38B | -62.12M -55.35M -51.25M -46.38M -87.37M -5.86B -88.41M -614M -241M -3.08B -233M -228M -9.82B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-21 | €0.8506 | -0.30% | 4,913,705 |
| 26-10-20 | €0.8532 | +3.09% | 5,636,560 |
| 26-10-19 | €0.8276 | -1.24% | 5,751,391 |
| 26-10-16 | €0.8380 | -2.83% | 5,369,596 |
| 26-10-15 | €0.8624 | +0.26% | 5,412,060 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PHARM Stock
Select your edition
All financial news and data tailored to specific country editions
